3-Chloromethcathinone

3-Chloromethcathinone (3-CMC), also known as clophedrone, is a synthetic substance belonging to the cathinone class of psychoactive compounds. It is very similar in structure to other methcathinone derivatives such as 3-MMC and 4-CMC. Unlike cathinone, which occurs naturally in the khat plant Catha edulis, 3-CMC is not found in nature and is solely produced through chemical synthesis.

First detected in 2014, 3-CMC gained attention for its stimulating effects that are described to be similar to the effects of mephedrone and, to a lesser extent, those of MDMA and cocaine. 3-CMC has been sold online as a designer drug mainly in European countries such as Germany, Poland, the Netherlands, and Sweden. It is a controlled substance in many countries.

Use

Recreational

The perceived effects are said to resemble those of 3-MMC, users report reduced effects and a shorter duration in comparison. Effects include stimulation, euphoria, and increased confidence, libido, and sociability. It can be administered orally or through nasal insufflation.

The acute effects of 3-CMC last 1 to 4 hours, depending on the administration method. After effects, like difficulty sleeping, can last 3 to 12 hours longer.

Availability

3-CMC has been available in Europe since 2014. According to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) it has been detected in 25 European countries with the majority of drug seizures in Poland and the largest quantities in the Netherlands. The amount of 3-CMC seized in Europe has increased yearly from 2014 to 2021 indicating an increase in production and availability. Large seizures of 3-CMC by customs are reported to originate from India.

Adverse effects

There are limited amounts of research available on the effects of 3-CMC. The effects are likely comparable to those of other cathinones of which it is known exposure can result in symptoms such as tachycardia, hypertension, and episodes of psychosis. Users also report other side effects including an increase in body temperature, sweating, anxiety, and dry mouth.

Toxicity

Information on the toxicity of 3-CMC is scarce, with only exploratory cytotoxicity studies conducted. Between November 2019 and June 2021, the EMCDDA reported ten deaths linked to 3-CMC exposure in Poland (7 cases) and Sweden (3 cases). Other substances were found in six cases, with alcohol being the only additional substance in two cases. Causes of death included multi-organ trauma caused by a traffic accident, toxic effects of 3-CMC, and intoxication with various substances. Details such as dosage and administration routes are lacking.

Chemistry

The chemical name of 3-chloromethcathinone (3-CMC) is 1-(3-chlorophenyl)-2-(methylamino)-1-propanone. It is a N-alkylated and ring-substituted cathinone derivative. The drug is the analogue of bupropion in which its ''N''- ''tert''-butyl group has been replaced with an ''N''-methyl group. Another related compound is 3-chlorocathinone (3-CC).

Isomers

3-CMC is a chloromethcathinone, which has two other positional isomers, namely 2-CMC and 4-CMC. These differ in the position of the chlorine atom on the phenyl ring. As well as 3-CMC, these molecules are both known designer drugs.

Since 3-CMC contains a chiral center, there are two enantiomers, namely (''S'')-3-CMC and (''R'')-3-CMC. The products are most likely on the market as a racemic mixture of the two enantiomers, since separation would result in very high costs.

Synthesis

Cathinones, including 3-CMC, can be synthesized via various routes. The simplest approach of the synthesis of ring-substituted cathinones is a 2-step bromination-animation reaction.

The first step is to produce 2-bromo-3-chloropropiophenone by the bromination of 3-chloro-propiophenone at the alpha-position under acidic or basic conditions. The second step involves an amination reaction using methylamine HCl, after which the final compound can be recrystallized and collected. The product is obtained as a racemic mixture, with the (''S'')-enantiomer thought to be more potent like other cathinones. Cathinones are usually unstable if they are not formed as a salt (ie. they turn into other compounds that are less active), so the final product is usually a chlorohydrate.
:

In case the starting aryl ketone precursor is unavailable or controlled, this precursor can be prepared by a standard Friedel-Crafts acylation reaction by mixing chlorobenzene with propionyl chloride in the presence of aluminium chloride.

Pharmacology

Pharmacodynamics

The pharmacology of 3-CMC is expected to be very similar to the pharmacology for other mephedrone analogs (methcathinones). These molecules interact with monoamine transporters, in particular the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT). The main function of these transporters is to terminate monoamine transmission by reuptake of the released neurotransmitters. Interaction of psychoactive drugs with the monoamine transporters inhibits this reuptake leading to an increase in the concentration of dopamine, norepinephrine and serotonin in the synaptic cleft.

Additionally 3-CMC and other mephedrone analogs are monoamine releasing agents (MRAs). They are transported into the cytoplasm of the nerve terminal through the monoamine transporters where they increase in the release of monoamine neurotransmitters. Releasers are thought to be more effective at raising monoamine levels since they enhance the pool of neurotransmitters available for release.

Psychostimulants differ in their relative affinity for DAT, SERT and NET. In a study done on brain cells of male rats 3-CMC was found to interact on a relatively similar level with DAT and NET as mephedrone, while it interacts significantly less with SERT. Another study done on male rats also concludes that 3-CMC causes more release of dopamine in proportion to serotonin whereas mephedrone releases relatively more serotonin.

3-CMC produces hyperlocomotion, a psychostimulant-like effect, in rodents. It substitutes for cocaine in drug discrimination tests in monkeys. The drug is less potent in substituting for cocaine than methcathinone, which has been theorized to be due to its greater capacity to induce serotonin release and to thereby inhibit its own reinforcing effects.

Pharmacokinetics

Cathinones are typically metabolized in the body through processes such as oxidation, reduction, hydrolysis, and conjugation reactions, primarily occurring in the liver.

There is still limited information about the metabolism of 3-CMC in humans or animals, as it has not been extensively studied. However, a mechanism has been proposed for the biotransformation processes of 3-CMC based on the metabolism of structurally similar cathinones, which involves the formation of several metabolites, including dihydro-3-CMC, ''N''-desmethyl-3-CMC, and ''N''-desmethyl-dihydro-3-CMC.
:

Legal status

As of March 2022, the European Commission has taken new measures to control the psychoactive substance of 3-CMC. This decision is based on a risk assessment conducted by the EU Drugs Agency (EMCDDA) in November 2021.

Since 3-CMC was prohibited in China (October 2015), it was found that most of the production was manufactured in India and little of the substance supply originates from inside Europe.

Several European countries were ahead of the European Commission report by (generically) controlling the substance. Nowadays, in almost all countries 3-CMC is prohibited.

See also

* 3-Chloro-''N''-cyclopropylcathinone (3Cl-CpC; PAL-433, RTI-6037-39)
* 3-Fluoromethcathinone
* 3-Fluoromethamphetamine
* 3-Methylmethcathinone
* 3-Chloromethamphetamine
* 4-Chloromethcathinone
* 5-Cl-bk-MPA
* Substituted cathinone

References

{{DEFAULTSORT:Chloromethcathinone, 3-
Cathinones
Designer drugs
3-Chlorophenyl compounds
Serotonin-norepinephrine-dopamine releasing agents